New Delhi, Dec 27 || Hyderabad-based drugmaker Indian Immunologicals Limited (IIL) on Saturday refuted claims by Australian health authorities over fake doses of its antirabies vaccine in India.
Earlier this week, the Australian Technical Advisory Group on Immunisation issued an alert that counterfeit batches of rabies vaccine Abhayrab have been circulating in India since November 2023.
IIL has been manufacturing Abhayrab in India since 2000.
In a statement, IIL “strongly refuted the over-cautionary and misplaced reference to 2023”, adding that the alert “does not reflect the current situation”.
“IIL aims to reassure stakeholders that the company’s pharmacovigilance and quality systems are robust, and that the public can continue to place confidence in vaccines supplied directly by IIL and its authorised channels,” added Sunil Tiwari, Vice President and Head of Quality Management at IIL, in the statement.
The company noted that since the year 2000, more than 210 million doses of Abhayrab have been supplied across India and 40 countries. The anti-rabies vaccine continues to hold a 40 per cent market share in India.